Dual Action Relief for Acidity & Gastric Discomfort

RABIFOL A
Rabeprazole 20 mg + Domperidone 30 mg SR Capsules

Product Overview:

RABIFOL A is a potent dual-action gastroprokinetic and acid-reducing formulation, combining Rabeprazole (a proton pump inhibitor) and Domperidone (a dopamine antagonist with prokinetic properties). This combination is highly effective in managing acid-related disorders, especially in patients with diabetes and cardiovascular conditions who are often at increased risk of gastrointestinal issues due to polypharmacy, stress, and lifestyle factors.

Mechanism of Action:

• Rabeprazole 20 mg: As a fast-acting PPI, Rabeprazole suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells. This leads to sustained acid control and promotes mucosal healing.

• Domperidone 30 mg (Sustained Release): Domperidone enhances gastrointestinal motility and accelerates gastric emptying. It acts by blocking dopamine receptors in the gut and the chemoreceptor trigger zone, thereby reducing nausea, vomiting, and bloating. The SR formulation ensures prolonged action and consistent relief.

Therapeutic Indications:

RABIFOL A is indicated for the management of:

1. Gastroesophageal reflux disease (GERD)

2. Functional dyspepsia

3. Non-ulcer dyspepsia

4. Diabetic gastroparesis

5. Acid peptic disorders associated with long-term NSAID use

6. Nausea and vomiting due to prokinetic dysfunction
   
   

   Key Benefits:

   Dual mechanism: Acid suppression + Prokinetic activity
   Rapid symptom relief and long-lasting control
   SR Domperidone ensures consistent action through the day
   Improves quality of life in cardiac and diabetic patients with gastrointestinal discomfort
   Well-tolerated with minimal side effects

Read this also 

Why Choose RABIFOL A?

For cardiac and diabetic patients, GI symptoms are often underdiagnosed yet significantly impact compliance and overall health outcomes. RABIFOL A addresses these challenges effectively by targeting both acid reflux and motility disorders. The combination ensures better patient adherence by reducing the pill burden and providing sustained relief throughout the day.

Dosage & Administration:
One capsule daily, preferably 30 minutes before breakfast or as directed by the physician.

Presentation:
Alu-Alu pack of 10 x 10 capsules, ensuring product stability and ease of dispensing.

Storage:
Store in a cool, dry place. Protect from light and moisture.

Conclusion:
RABIFOL A is the ideal choice for modern clinical practice, providing comprehensive relief in acid reflux and motility-related conditions. It is particularly suitable for long-term use in patients with comorbid conditions like diabetes and cardiovascular disease, where gut health is essential for overall treatment success.